149 related articles for article (PubMed ID: 16213010)
1. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.
Guminski AD; Balleine RL; Chiew YE; Webster LR; Tapner M; Farrell GC; Harnett PR; Defazio A
Gynecol Oncol; 2006 Feb; 100(2):239-46. PubMed ID: 16213010
[TBL] [Abstract][Full Text] [Related]
2. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
Surowiak P; Materna V; Kaplenko I; Spaczynski M; Dolinska-Krajewska B; Gebarowska E; Dietel M; Zabel M; Lage H
Clin Cancer Res; 2006 Dec; 12(23):7149-58. PubMed ID: 17145840
[TBL] [Abstract][Full Text] [Related]
3. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.
Materna V; Pleger J; Hoffmann U; Lage H
Gynecol Oncol; 2004 Jul; 94(1):152-60. PubMed ID: 15262134
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
5. Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells.
Itoh Y; Tamai M; Yokogawa K; Nomura M; Moritani S; Suzuki H; Sugiyama Y; Miyamoto K
Anticancer Res; 2002; 22(3):1649-53. PubMed ID: 12168849
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer.
Ushijima R; Takayama K; Izumi M; Harada T; Horiuchi Y; Uchino J; Hara N; Nakanishi Y
Anticancer Res; 2007; 27(6C):4351-8. PubMed ID: 18214043
[TBL] [Abstract][Full Text] [Related]
7. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.
Materna V; Stege A; Surowiak P; Priebsch A; Lage H
Biochem Biophys Res Commun; 2006 Sep; 348(1):153-7. PubMed ID: 16876126
[TBL] [Abstract][Full Text] [Related]
8. Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats.
Hoffmann K; Gastens AM; Volk HA; Löscher W
Epilepsy Res; 2006 Apr; 69(1):1-14. PubMed ID: 16504477
[TBL] [Abstract][Full Text] [Related]
9. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
Materna V; Liedert B; Thomale J; Lage H
Int J Cancer; 2005 Jun; 115(3):393-402. PubMed ID: 15688364
[TBL] [Abstract][Full Text] [Related]
10. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter.
Smeets PH; van Aubel RA; Wouterse AC; van den Heuvel JJ; Russel FG
J Am Soc Nephrol; 2004 Nov; 15(11):2828-35. PubMed ID: 15504935
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
Liedert B; Materna V; Schadendorf D; Thomale J; Lage H
J Invest Dermatol; 2003 Jul; 121(1):172-6. PubMed ID: 12839578
[TBL] [Abstract][Full Text] [Related]
12. Role of glycosylation in trafficking of Mrp2 in sandwich-cultured rat hepatocytes.
Zhang P; Tian X; Chandra P; Brouwer KL
Mol Pharmacol; 2005 Apr; 67(4):1334-41. PubMed ID: 15662046
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
14. MRP2 Inhibition by HIV Protease Inhibitors in Rat and Human Hepatocytes: A Quantitative Confocal Microscopy Study.
Holmstock N; Oorts M; Snoeys J; Annaert P
Drug Metab Dispos; 2018 May; 46(5):697-703. PubMed ID: 29523599
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
[TBL] [Abstract][Full Text] [Related]
16. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.
Vlaming ML; Mohrmann K; Wagenaar E; de Waart DR; Elferink RP; Lagas JS; van Tellingen O; Vainchtein LD; Rosing H; Beijnen JH; Schellens JH; Schinkel AH
J Pharmacol Exp Ther; 2006 Jul; 318(1):319-27. PubMed ID: 16611851
[TBL] [Abstract][Full Text] [Related]
17. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
[TBL] [Abstract][Full Text] [Related]
18. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
19. Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice.
Wen X; Buckley B; McCandlish E; Goedken MJ; Syed S; Pelis R; Manautou JE; Aleksunes LM
Am J Pathol; 2014 May; 184(5):1299-308. PubMed ID: 24641901
[TBL] [Abstract][Full Text] [Related]
20. Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human.
Li N; Zhang Y; Hua F; Lai Y
Drug Metab Dispos; 2009 Jan; 37(1):66-73. PubMed ID: 18832477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
